A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions

Neoplasms Malignant

Interventions

DRUG

AK112

AK112 is a PD1/VEGF bispecific antibody.

Trial Locations (7)

Border Medical Oncology, Albury

Scientia Clinical Research Ltd, Randwick

Blacktown Hospital, Sydney

ICON Cancer Foundation, South Brisbane

Adelaide Cancer Centre, Kurralta Park

Monash Health, Clayton

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors

lead

Akesobio Australia Pty Ltd

INDUSTRY

NCT04047290 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors | Biotech Hunter | Biotech Hunter